PS17/25 – Matching Adjustment Investment Accelerator
Executive Summary
PS17/25 establishes the **Matching Adjustment Investment Accelerator (MAIA) framework**, enabling PRA-regulated insurers to regularize and expand their use of matching adjustment (MA) in calculating capital requirements for certain long-duration insurance liabilities. This framework is significant because it provides a structured pathway for firms to optimize capital efficiency while maintaining prudential safeguards through exposure limits, eligibility assessments, and breach remediation mechanisms.
What Changed
- The MAIA framework introduces the following regulatory requirements: Permission and Eligibility Framework
- Firms must obtain explicit MAIA permission from the PRA to use the accelerator
- Permission grants authority to regularize previously non-compliant MA assets and apply MA to new eligible assets within defined parameters Exposure Limits
- Firms receive fixed monetary exposure limits calibrated using the Best Estimate of Liabilities (BEL) of the MA portfolio, net of reinsurance, at the time of permission grant
- Limits remain fixed until the next formal variation of MAIA permission Asset Eligibility and Assessment
- Firms must apply a proportionate, risk-based approach to assessing asset eligibility, with more in-depth assessment required for assets involving greater judgment
Suggested Considerations
- *Immediate (Q4 2025 - Q1 2026):
- *Assess eligibility for MAIA permission by reviewing current MA portfolio and prospective assets
- *Develop MAIA policy documenting asset eligibility criteria, governance structure, and risk management approach
- *Establish contingency plans for scenarios where MAIA assets become ineligible
- *Prepare MAIA permission application if pursuing the framework
- *Review and update MI, reporting, and control capabilities to support MAIA compliance
Key Dates
Compliance Impact
Urgency: HIGH
Who is Affected
References
AI-generated analysis. May contain errors or omissions — verify with the original PRA source before acting. Full disclaimer.
Summary
Policy statement 17/25